5. If the status quo persists
If Trump is reelected and Republicans and Democrats maintain control of the Senate and the House, respectively, little is likely to change in terms of drug pricing. Recent history underscores the difficulty of launching comprehensive healthcare reform. Trump’s drug-pricing executive orders “don’t have a huge amount of teeth, and probably don’t hold up legislatively if the industry were to sue to get them thrown out,” Caliendo said.
If the status quo continues, “passing any drug pricing legislation becomes less certain,” surmised Geoffrey Porges, an analyst at the investment bank SVB Leerink in a client note.